Company had a strong start to 2025, emerging as an R&D-focused organization Exclusive license agreement with Novo Nordisk for LX9851 executed; IND-enabling studies on track for completion in 2025 Phas ...

Acne vaccine which is currently in Phase I/II trials, targets acne bacteria using mRNA technology and may revolutionize ...

Pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer and the fourth leading cause of cancer-related death, has a 5-year survival rate of less than 10%.1 The impact of pancreatic ...

While the US leads in early-phase obesity trials and investment, the country also faces challenges in disease burden, trial ...

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

Lexeo Therapeutics, Inc.’s LXEO share price has surged by 17.04%, which has investors questioning if this is right time to ...

Despite groundbreaking advances in pediatric cancer research, many promising therapies never reach the children who need them most. Catherine Bollard, MD, is senior vice president and chief research ...

Significant adverse events — such as ARIA — with lecanemab, the drug that slows Alzheimer's, is rare and manageable, ...

Discover 9 promising small molecule drug discovery companies that recently raised funding for their potentially breakthrough ...

A decades-long scientific challenge in HIV vaccine development has been finding a way to train the immune system to produce antibodies that can target many variants of the virus.

Close collaboration between researchers and clinicians at Mayo is what makes the steps of translation — from discovery to the ...